Skip to main content

Dyne Therapeutics, Inc 10-Q for FY2026 Q3

Dyne Therapeutics, Inc. (DYN)

10-Q 2026-11-05 For: 2026-09-30
View Original
Added on November 05, 2026

About this 10-Q

Dyne Therapeutics, Inc filed this 10-Q on November 5, 2026, covering the quarter ended September 30, 2026 (FY2026 Q3).

Dyne Therapeutics’ FDA accepted the BLA for z-rostudirsen in DMD, with priority review and a PDUFA target date of January 21, 2027; potential U.S. launch is expected in the first quarter of 2027. AI summary

Headline figures

Quarter ended September 30, 2026, as reported in this filing, compared with the same period a year earlier where the filing states it.

Net loss
$193.55M
compared with a net loss of $108.04M a year earlier
Diluted EPS
-$1.06
compared with -$0.76 a year earlier